BLOOD glucose has only recently emerged as an important variable in critical care. In the past, this biologic marker has been largely ignored or considered as adaptive to the stress conditions observed in critically ill patients. In this issue of Anesthesiology, Egi et al.  1report observations from a large database that included 7,049 critically ill patients in whom blood glucose was frequently monitored. They observed that variability of blood glucose concentration was an independent predictor of intensive care unit (ICU) and hospital mortality.

It is now obvious that blood glucose plays a key role in both the short- and long-term consequences of neurologic injury.2,3In the heart, high blood glucose level abolishes ischemic preconditioning,4amplifies reperfusion injuries,5and provokes coronary endothelial dysfunction6,7and thus further increases the incidence of myocardial ischemic events. Numerous clinical studies have identified diabetes mellitus as an independent risk factor for perioperative morbidity and mortality,8and there is compelling evidence that perioperative glycemic control improves early clinical outcome of diabetic patients.9In a randomized study in critically ill patients, Van der Berghe et al.  10reported that intensive insulin therapy is associated with a lower mortality. In patients undergoing coronary artery bypass surgery, we have recently demonstrated that a poor intraoperative glucose control despite intensive insulin therapy is associated with a worsened hospital outcome in diabetic patients.11As emphasized recently by Malhotra,12the days of ignoring blood glucose levels or tolerating marked hyperglycemia in the ICU are over.

In the report by Egi et al. ,1blood glucose was closely monitored; on average, glucose was measured every 4 h. The mean measures were 24 per patient, and the variability of blood glucose predicted ICU and hospital mortality. In multivariate analyses, the odds ratio associated with blood glucose variability (1.28 per 1 mm of SD) and that associated with mean blood glucose (1.21 per 1 mm) were comparable in predicting ICU mortality. The results were comparable when considering hospital mortality. These results should be considered with caution because this was a retrospective study and we cannot rule out the possibility of hidden bias. Although these results are impressive and the methodology used is appropriate, including a very large number of critically ill patients, it should be noted that these associations were observed; however, this does, in itself, not prove causality. Therefore, the study from Egi et al.  1should be considered as the first important step toward a new paradigm concerning the prognostic value of blood glucose concentrations: Not only the level of blood glucose but also its variability might be of paramount importance. This study constitutes a unique opportunity to orient future research, both experimental and clinical, to test this new hypothesis.

If blood glucose variability is as important as blood glucose level, some recent findings should be reconsidered. For example, using intensive insulin therapy in the ICU, the first study by Van der Berghe et al.  10showed a reduction in mortality, whereas a second large trial did not.13Many factors might explain this discrepancy.12However, it should be pointed out that neither of these clinical trials assessed blood glucose variability, which might have played a crucial role. Two large ongoing randomized trials on intensive insulin therapy in the ICU might also consider blood glucose variability as an important factor.*†

Blood glucose variability has been simply assessed by the SD (or the coefficient of variation) in the study by Egi et al.  1However, this variable is in fact a very complex factor that could encompass several pathophysiologic processes: variation of blood glucose around abnormal high values, variation of blood glucose between abnormal high (hyperglycemia) and low (hypoglycemia) values. Future research should be also directed to assess the more appropriate definition of blood glucose variability and to delineate the possible pathophysiologic mechanisms involved. The initial results of blood glucose variability as insulin treatment is initiated should probably be discarded. Also, this may depend on the therapeutic effort to maintain blood glucose using intensive insulin therapy. The mode of administration of insulin may affect blood glucose variability; continuous intravenous administration is better than continuous and bolus subcutaneous administration, which is better than intravenous bolus administration. Insulin itself may also induce biologic effects aside from glycemic variation; these include a decrease in level of free fatty acids, scavenging of free radicals, and even nonmetabolic biologic actions.14–17Here, it should be emphasized that the results observed by Egi et al.  12may not apply to critically ill patients receiving intensive insulin therapy.

In the study by Egi et al.  1and in a subgroup analysis, the results were not markedly modified based on whether the patients were diabetic. Also, the sample size for diabetic patients was too small to test their blood glucose level and blood glucose variability. This is important because there is evidence that the deleterious effects associated with high blood glucose in critically ill patients are not the same in diabetic and nondiabetic patients.18Moreover, diabetes should not be considered as a single disease because there are marked differences in diabetes types I and II. Blood glucose variability is usually less pronounced in type II diabetic patients in whom endogenous insulin secretion exists. We therefore suggest that the hypothesis for a critical role of blood glucose variability should be tested separately in nondiabetic patients and diabetic critically ill patients. Even diabetic patients should be divided by type and will require a very large multicenter study.

In conclusion, blood glucose variability and not only blood glucose level should probably be taken into account in future research on perioperative glucose monitoring and outcome. This is not really surprising because blood glucose variability has long been considered as important for the long-term care of diabetic patients.

‡Department of Anesthesiology and Critical Care, §Department of Diabetology, ∥Department of Anesthesiology and Critical Care and Department of Emergency Medicine and Surgery, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université Pierre et Marie Curie (Paris 6), Paris, France.

Egi M, Bellomo R, Stachowski E, French CJ, Hart G: Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006; 105:244–52
Frontera JA, Fernandez A, Claassen J, Schmidt M, Schumacher HC, Wartenberg K, Temes R, Parra A, Ostapkovich ND, Mayer SA: Hyperglycemia affect SAH: Predictors, associated complications, and impact on outcome. Stroke 2006; 37:199–203
Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC: Relationship of early hyperglycemia to mortality in trauma patients. J Trauma 2004; 56:1058–62
Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC: Diabetes abolishes ischemic preconditioning: Role of glucose, insulin and osmolality. Am J Physiol 2000; 278:H1218–24
Verma S, Maitland A, Weisel RD, Li S, Fedak PWM, Pomroy NC, Mickle DAG, Li R, Ko L, Rao V: Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: Reversal with endothelin antagonism. J Thorac Cardiovasc Surg 2002; 123:1120–4
Koltai MZ, Hadhazy P, Posa I, Kocsis E, Winkler G, Rosen P, Pogatsa G: Characteristics of coronary endothelial dysfunction in experimental diabetes. Cardiovasc Res 1997; 34:157–63
Gross ER, LaDisa JF, Weihrauch D, Olson LE, Kress TT, Hettrick DA, Pagel PS, Warltier DC, Kersten JR: Reactive oxygen species modulate coronary wall shear stress and endothelial function during hyperglycemia. Am J Physiol 2003; 284:H1552–9
Kersten JR, Warltier DC, Pagel PS: Aggressive control of intraoperative blood glucose concentration: A shifting paradigm? Anesthesiology 2005; 103:677–8
Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Storm Flotem H, Starr A: Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125:1007–21
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359–67
Ouattara A, Lecomte P, Le Manach Y, Landi M, Jacqueminet S, Platonov I, Bonnet N, Riou B, Coriat P: Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology 2005; 103:687–94
Malhotra A: Intensive insulin therapy in intensive care. N Engl J Med 2006; 345:516–8
Van der Berghe G, Wilmer A, Hermans G, Meersserman W, Wouters PJ, Milans I, Van Wijngaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in medical ICU. N Engl J Med 2006; 345:449–61
Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS: Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 109:1497–502
Langouche L, Vanhorebeek I, Vlasselaers D, Vander Perre S, Wouters PJ, Skogstrand K, Hansen TK, Van den Berghe G: Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005; 115:2277–85
Hess ML, Okabe E, Poland J, Warner M, Stewart JR, Greenfield LJ: Glucose, insulin, potassium protection during the course of hypothermic global ischemia and reperfusion: A new proposed mechanism by the scavenging of free radicals. J Cardiovasc Pharmacol 1983; 5:35–43
Brown RT, Polinsky RJ, Lee GK, Deeter JA: Insulin-induced hypotension and neurogenic orthostatic hypotension. Neurology 1986; 36:1402–6
Puskas F, Grocott H, White W, Mathew J, Newman M, Bar-Yosef S: Hyperglycemia and increased incidence of cognitive deficit after cardiac surgery. Anesth Analg 2005; 100:SCA1–116